peptide mapping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-26. Anything still debated is marked as such rather than presented as settled.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
During the subsequent decades, however, many large protein regions could not be assigned in x-ray datasets, indicating that they occupy multiple positions, which average out in electron density maps. The lack of fixed, unique positions relative to the crystal lattice suggested that these regions were "disordered". Nuclear magnetic resonance spectroscopy of proteins also demonstrated the presence of large flexible linkers and termini in many solved structural ensembles. In 2001, Dunker questioned whether information was ignored for 50 years with more quantitative analyses becoming available in the 2000s. In the 2010s it became clear that IDPs are common among disease-related proteins, such as alpha-synuclein and tau.
DMT derived from plant-based sources has been used as an entheogen in South America for thousands of years. DMT was first synthesized in 1931 by Canadian chemist Richard Manske. In general, its discovery as a natural product is credited to Brazilian chemist and microbiologist Oswaldo Gonçalves de Lima, who isolated an alkaloid he named nigerina (nigerine) from the root bark of Mimosa tenuiflora in 1946. However, in a careful review of the case Jonathan Ott shows that the empirical formula for nigerine determined by Gonçalves de Lima, which notably contains an atom of oxygen, can match only a partial, "impure" or "contaminated" form of DMT. It was only in 1959, when Gonçalves de Lima provided American chemists a sample of Mimosa tenuiflora roots, that DMT was unequivocally identified in this plant material. Less ambiguous is the case of isolation and formal identification of DMT in 1955 in seeds and pods of Anadenanthera peregrina by a team of American chemists led by Evan Horning (1916-1993). Since 1955, DMT has been found in a number of organisms: in at least fifty plant species belonging to ten families, and in at least four animal species, including one gorgonian and three mammalian species (including humans). In terms of a scientific understanding, the hallucinogenic effects of DMT were not uncovered until 1956 by Hungarian chemist and psychiatrist Stephen Szára.
21 July The Bodyhunters, about the disappearance of Royal Marine Alan Addis; on 8 August 1980, Royal Marine went missing in North Arm; the Forensic Search Advisory Group, from the Home Office, was founded in 1988 by forensic archaeologist John Hunter of the University of Birmingham, with Sgt Mick Swindells of Lancashire Constabulary, providing the first evidence by an archaeologist in a British court; Swindells had found 5 yr old Rosie McCann, of Moorheys in Oldham, in only a few hours in March 1996, after she had disappeared on 14 January 1996 - the local police had been, conversely, searching for seven weeks and had not found anything in that time, and with the generous assistance of RAF search teams; the FSAG adopted a much different searching approach to typical police methods, with archaeology, more educated guesses, and applied geophysics; the individual was part of Naval Party 8901, to train locals in civil defence in 1980; Islands Radio; the team took ground-penetrating radar and five local policemen; three years previously detectives from Devon and Cornwall Police conducted an investigation and arrested four people - three of those were Titch Jaffray, Burnerd Peck and Tony Blake; the team were conducting a nine-day search in 1997; 80-90% of murders have disposal in known areas to the murderer; Chris Johnson was a former Royal Marine; the team looked in the cemetery first, with ground-penetrating radar, which could detect up to three metres below the surface, for irregularities; Tim Cotter, from the Royal Navy; the team knew that any disused buildings would be a plausible hiding place, as nothing is often suspected; in a search site, the team found mixed, or disturbed, soil. Narrated by Robin Ellis, made with the Discovery Channel 28 July Miracle Police, including the Audrey Santo case; personnel of the Roman Catholic Diocese of Worcester; the investigator Joe Nickell; Peter Gumpel of the Congregation for the Causes of Saints; evolutionary psychologist Robin Dunbar; John Polkinghorne of the University of Cambridge; Karen Armstrong, who wrote A History of God; the Lourdes Medical Bureau; Luigi Bommarito, Archbishop from 1988 to 2002 of the Roman Catholic Archdiocese of Catania. Narrated by Piers Gibbon, directed by Alexander Marengo, made by Ideal World with the Discovery Channel 4 August Dawn of the Death Ray, about the laser and its invention in July 1960; physicist Arthur Schawlow, inventor of the laser; testing of lasers took place at Kirtland Air Force Base, New Mexico, where an aircraft was first brought down with a laser in November 1973; a laser-equipped Boeing KC-135 was operated from 1973, by the 4900th Flight Test Group, led by Col John Otten, taking off in January 1975; fighter aircraft would launch air to air missiles, with insufficient fuel, at the aircraft, and the laser would attempt to shoot the missile down; after three years, on 26 May 1983, the laser shot down its first air to air Sidewinder missile; adverse atmospheric conditions often made an airborne laser ineffective; the White Sands Missile Range in New Mexico, and Leik Myrabo of the USAF Advanced Concepts Division; the 1991 Gulf War allowed much advanced technology to be fully evaluated - and Patriot missiles had mostly missed Iraqi Scud missiles; the Directed Energy Directorate of the Air Force Research Laboratory, and its Starfire Optical Range, and physicist Robert Fugate; John V. Breakwell; the USAF ordered seven airborne attack lasers, for delivery by 2008; Major-General Don Lamberson. Narrated by Michael Bywater, directed by Chris Durlacher, produced by David Dugan, made by Windfall Films 11 August Thin Air, about climbers on Mount Everest; in the 1996, eight participants on an Everest expedition died in one day; above 17,000 ft climbers experience weight loss and sleep loss; Peter Hackett (mountaineer); Ed Viesturs from Seattle; David Breashears, who made the documentary; when he was making a film in May 1996, eight climbers died in the 1996 Mount Everest disaster; climbers fly by helicopter to 9,000 ft, then climb to base camp at 17,600 ft; pulmonologist Brownie Schoene of the University of Washington School of Medicine in Seattle; psychologist Gail Rosenbaum; chronic mountain sickness and the portable hyperbaric bag, which is pumped to 2 PSI; the Khumbu Glacier and Khumbu Icefall; Guy Cotter of Adventure Consultants; the 'death zone' is above 26,000 ft; the Lhotse western face; the team reach the South Col, known as Camp VI; the Hillary Step; pulse oximetry and brain MRI scans are taken in Seattle. Broadcast on PBS as Everest - the death zone, when narrated by Jodie Foster. British edition narrated by Piers Gibbon, directed by David Breashears, made by Nova 18 August The Ten Plagues of Egypt, about the Plagues of Egypt in the Book of Exodus; Avi Weiss, who researched the Book of Exodus; doctor John S. Marr looked at the Ipuwer Papyrus, and worked with Curtis Malloy; marine biologist JoAnn Burkholder of North Carolina State University, and how Pfiesteria piscicida could be the first plague; Richard Wassersug of Dalhousie University in Canada, and a plague of frogs; entomologist Richard Brown of Mississippi State University in Starkville, Mississippi; public health entomologist Andrew Spielman of Harvard T.H. Chan School of Public Health; Roger Breeze of Plum Island Animal Disease Center; the final plague was likely caused by Stachybotrys chartarum, which made mycotoxin. Narrated by Jenni Murray, produced by Peter Spry-Leverton, directed by Bill Eagles, made by UFA GmbH and Café Productions, with The Learning Channel
This may account for the curious fact that proline is usually solvent-exposed, despite having a completely aliphatic side chain. Multiple prolines and/or hydroxyprolines in a row can create a polyproline helix, the predominant secondary structure in collagen. The hydroxylation of proline by prolyl hydroxylase (or other additions of electron-withdrawing substituents such as fluorine) increases the conformational stability of collagen significantly. Hence, the hydroxylation of proline is a critical biochemical process for maintaining the connective tissue of higher organisms. Severe diseases such as scurvy can result from defects in this hydroxylation, e.g., mutations in the enzyme prolyl hydroxylase or lack of the necessary ascorbate (vitamin C) cofactor.
Sources: en.wikipedia.org
Smallpox was eradicated by a massive international search for outbreaks, backed up with a vaccination program, starting in 1967. It was organised and co-ordinated by a World Health Organization (WHO) unit, set up and headed by Donald Henderson. The last case in the Americas occurred in 1971 (Brazil), south-east Asia (Indonesia) in 1972, and on the Indian subcontinent in 1975 (Bangladesh). After two years of intensive searches, what proved to be the last endemic case anywhere in the world occurred in Somalia, in October 1977. A Global Commission for the Certification of Smallpox Eradication chaired by Frank Fenner examined the evidence from, and visited where necessary, all countries where smallpox had been endemic. In December 1979 they concluded that smallpox had been eradicated; a conclusion endorsed by the WHO General Assembly in May 1980. However, even as the disease was being eradicated there still remained stocks of smallpox virus in many laboratories. Accelerated by two cases of smallpox in 1978, one fatal (Janet Parker), caused by an accidental and unexplained containment breach at a laboratory at the University of Birmingham Medical School, the WHO ensured that known stocks of smallpox virus were either destroyed or moved to safer laboratories. By 1979, only four laboratories were known to have smallpox virus.
The distinction between Jack and the player has also informed debate over ludonarrative dissonance, a term introduced by game designer Clint Hocking in a 2007 critique of BioShock. Hocking argued that the game permits players to pursue self-interest through its mechanics while obliging Jack to help Atlas through its narrative, creating a conflict between the values expressed through play and those expressed through the story. In a 2026 reassessment, Connor Jackson disputed this reading. Jackson argued that Jack's conditioning provides an in-universe explanation for his obedience to Atlas and cautioned against assuming that the motivations of a controllable avatar must correspond to those of the player. He also emphasized that the rescue-or-harvest decisions concerning the Little Sisters have substantial narrative consequences, and therefore considered BioShock's treatment of agency more complex than a simple contradiction between an inflexible story and flexible gameplay. Jennings identified this disagreement as characteristic of the wider scholarship on BioShock. Although many studies have treated the game as evidence that video-game agency is fundamentally illusory, others have distinguished between different kinds and degrees of agency rather than treating control as either wholly present or absent. She argued that even choices constrained by a designed system can produce meaningful experiences of responsibility, investment, and interpretation, and used the extensive debate surrounding BioShock to argue for a more contingent understanding of agency in games.
==== School of Education & Urban Studies ==== The School of Education houses the teacher education and institution administrator programs. The teacher education program is accredited by the Council for the Accreditation of Educator Preparation (CEAP).
=== Opioid overdose and/or opioid use disorder === Methocinnamox is able to reverse the respiratory depressant effects of fentanyl and heroin in animals. However, unlike naloxone, another opioid antagonist, its action lasts around 2 weeks if administered subcutaneously and up to 5 days if administered intravenously. This could make it a better antidote than naloxone in opioid overdoses, because naloxone usually lasts around 30 minutes, there is a need for repeated administration and a danger of renarcotization. By acting longer, methocinnamox prevents these dangers. Methocinnamox has not yet been tested in humans as of 2022. However, it has been tested in rodents and monkeys. It was reported in March 2020 that clinical trials of methocinnamox were expected to begin within 18 to 24 months. In March 2023, it was reported that a phase 1 clinical trial of methocinnamox funded by the National Institutes of Health (NIH) would possibly start in 2024.
Curare is an alkaloid poison extracted from native South American plants in the Chondrondendron genus. They were initially used by indigenous groups as a paralyzing agent for hunting. European scientists later discovered that tubocurarine was the major constituent responsible for the paralyzing effect by acting on the neuromuscular junction. Anasthesiologists Harold Griffith and Enid Johnson first documented the successful use of curare, in a clinical trial to facilitate muscle relaxation in a healthy patient undergoing appendicectomy in 1942. Before the use of curare, anesthesiologist required large doses of anesthetic such as chloroform to achieve similar paralyzing effects, hence increased the risk of life-threatening effects in elderly patients who had cardiac complications. Ever since, neuromuscular agents have been commonly used in practice during anesthetic procedures. The clinical trial conducted by Griffith and Johnson also paved the way for discovery of many more neuromuscular drugs for surgical use.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It separates molecules by hydrophobicity, which is effective for distinguishing an intact peptide from truncated or chemically modified forms. A C18 column with an acidic water-organic mobile phase is a standard configuration.